Bertassoni is the founding director of the Knight Cancer Precision Biofabrication Hub and an associate professor at the Division of Oncological Sciences at the Knight Cancer Institute. He leads a multidisciplinary research group working on micro-scale technologies and bioprinting for tissue regeneration and disease modeling and holds appointments at the Department of Biomedical Engineering, the Cancer Early Detection Advanced Research center (CEDAR) and the OHSU School of Dentistry.
After obtaining his PhD in Biomaterials from University of Sydney, Bertassoni was a postdoctoral researcher at UCSF, and subsequently at Harvard and MIT.. He has published more than 90 manuscripts, received more than 30 national and international research awards, including the New Investigator award by the Medical Research Foundation, the IADR Centennial award, and the OHSU Faculty Excellence and Innovation award. He serves as associate editor or editorial board member for 10 journals, and is a co-founder of two biotech spin-off companies, which resulted from his work on cancer research (HuMarrow Inc.), and regenerative medicine (RegendoDent Inc).